H.R. 1051
To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
Session
119th Congress Current
Status Pending
Referred to the House Committee on Energy and Commerce.Sponsors (1)
NBNikki Budzinski
Democrat · Primary
Legislative Votes
No votes have been held on this legislation yet.